Drug Trial Radar · NCT07228078
Open-Label Extension Protocol to SNK01-AD01 Study
Last checked: Nov 19, 2026Latest source record: Nov 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jun 30, 2025
Primary completion
Apr 2028
Study completion Apr 2028
Sponsor
- Lead sponsor
- NKGen Biotech, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-Label Extension Protocol to SNK01-AD01 Study
Conditions
- Alzheimer Disease
Interventions
SNK01Biological
SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0Time frame: 1 Year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Behavioral Research Specialists, LLC
Glendale, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.